{"ticker": {"uuid": "4340f5c3-b986-4fdb-a6db-e2ac0a2332c2", "symbol": "CELU", "name": "Celularity Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Insider trust lends $1M to Celularity (NASDAQ: CELU) on short term", "summary": "Celularity Inc. has secured a $1 million short-term loan from the Philip & Daniele Barach Family Trust, an entity linked to a significant shareholder. The loan features a 4.0% annual interest rate, which can rise to 18.0% upon default, and is collateralized by most of Celularity'", "url": "https://www.stocktitan.net/sec-filings/CELU/8-k-celularity-inc-reports-material-event-3578c6e71049.html", "source_name": "Stock Titan", "published_at": "2026-06-30T22:09:35", "published_display": "30 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc. Enters into a Loan Agreement with the Philip & Daniele Barach Family Trust", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQd2xIZ0NmaXU1eExmWlRoMEwyNHA0S0FSYXhhMEJXSDRIMlBOa2pIc0tkV1RxcU5qQTdGc1NBbHZYd2t4aGxXbXBMelVJdnRMcXZwVnVaS1Q1UDVwRGNObnhYWlVEemRQdzFKb2l2YnpMT1Y5VF83TzcyLWJWektJTVBvdUxpNGhXSk4wT041X2NWUzFRd3RJdkJ6aEc4Yk9FcjRyVTRyZ3luTzZndng1dTZCcWhmTnR5T1QxQnE3RjEyWGFGZkdzS0pBSjRzQ0JuaXNYS3RWcw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-30T19:35:42+00:00", "published_display": "30 Jun 2026 19:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc (NASDAQ: CELU) Share Price, CELU Stock News, CELU Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE1IX1NTTlpDMERiVko1ajlCMkhLUVFmV1Iyc2FreU1LRXRKWEtwUTdaN1MweEd0T2xDbmZaRTR4aGdaQzN1VHZtTGNhSnhLbHdGRG9IczNn?oc=5", "source_name": "Kalkine", "published_at": "2026-06-29T10:46:46+00:00", "published_display": "29 Jun 2026 10:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Appoints Chief Operating Officer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/celularity-appoints-chief-operating-officer-094945297.html", "source_name": "MT Newswires", "published_at": "2026-06-26T09:49:45+00:00", "published_display": "26 Jun 2026 09:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc. Class A Actuals & Estimates (NASDAQ:CELU)", "summary": "This article provides an overview of Celularity Inc. (NASDAQ: CELU) stock, including its current price, market capitalization, volatility, and historical performance. It also details financial information such as net income, EBITDA, and the upcoming earnings release date, along w", "url": "https://www.tradingview.com/symbols/NASDAQ-CELU/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:12:30", "published_display": "25 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 10, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New leadership at Celularity (NASDAQ: CELU) as Gordon joins board", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxORG5lN3hXT3FwcVRKVTVSN2sxc2tQY1hPd3hpZXdVVmdvME1PbENLRzdwMENjb28zc1RpcGU0dHZYS24wXzNoMk02R3F5WmlhMnpJRFVRTzBGTVNtWm1SYmJlLXhGcWZidE02Y0Frc1FEd3loOUttSFZ6WkhvWF9xRjRnNWpzRjBBSFFVRDhsMWRmMVN3bGdPOGhMblpzUUk5RVJ2dEhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc. (CELU) Q4 2025 Earnings: Narrowed Loss Beats Estimates, but Revenue Remains Absent - Diluted EPS Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOWFdieVp3dmNuNjFJSUJabHA2VmVMeVpzVGJPVGdLTTZBN3Q2WXJGZFo2V2tkY1ZtamNPSGQ3YUJkQkY4UkdJWGZVdnp0VXZZUnRYMkRqU0FTWU5tQUxDTWhEeFRRZEhrVVJ5bVpwUm9raGtXcGpVc0JPLTdTWEJicmljTkM1TmVmTmoyd0NXNjVrMWR3LURiVTl2T3ltcDJoLVJQc0FTYWZPUExYOWZaeHVLbGRfQjZpMnhuZGFvck9IMHRXbUtRNGRjS2VoenFnaHhkeVVKbGU?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Celularity Inc For: 23 June By Investing.com", "summary": "This article confirms that a Form 4 filing for Celularity Inc. was made on June 23rd, as reported by Investing.com. It also briefly mentions Celularity Inc.'s stock symbol CELU and its performance. The rest of the content includes current market data for various indices, commodit", "url": "https://ng.investing.com/news/stock-market-news/form-4-celularity-inc-for-23-june-93CH-2570399", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T19:10:35", "published_display": "23 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) insider trust sees $2M note option expire", "summary": "A Form 4 filing reveals that options held by The Philip & Daniele Barach Family Trust, a ten percent owner of Celularity (NASDAQ: CELU), to purchase up to $2,000,000 in convertible notes and 839,160 related warrants, expired on June 19, 2026. The expiration occurred as per the te", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-0d6ae59ebe9e.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:11:47", "published_display": "23 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barach Family Trust (CELU) lets $2M note, warrant options lapse while holding large derivatives", "summary": "The Philip & Daniele Barach Family Trust, a 10% owner of Celularity Inc. (CELU), reported that options to purchase $2 million in convertible notes and 839,160 warrants expired on June 19, 2026, without consideration. Despite these expirations, the trust maintains significant hold", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-bac6c5ce9bad.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:11:47", "published_display": "23 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) major holder\u2019s $2M note option and 839K warrants expire", "summary": "A major shareholder of Celularity Inc., Daniele Wolf Barach, through the Philip & Daniele Barach Family Trust, reported the expiration of options to purchase up to $2 million in convertible notes and rights to obtain 839,160 warrants. These options expired on June 19, 2026, witho", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-cb12e457913a.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:11:47", "published_display": "23 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Celularity Inc. For: 23 June By Investing.com", "summary": "This article announces the filing of Form 13D/A by Celularity Inc. on June 23, 2026. Form 13D/A is a regulatory filing indicating a change in beneficial ownership of a company's shares. The article provides no further details about the filing's content.", "url": "https://ng.investing.com/news/stock-market-news/form-13da-celularity-inc-for-23-june-93CH-2569437", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T07:09:59", "published_display": "23 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penny Stocks: Why Is Celularity (CELU) Stock Trending Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPSld5eEhZLVpzWEJGTWhFak9DZExLZ2dFbmNpMHFtbVJxTGt0WHRqdGJWZWJGcVJ4dmFkMVRmQjJrQkczVUoxQnM5Zm9IZlBzQzNsNXdoekZrenZPRXYtZTVLRUQ1YnIyNWZ1MF9QMzFXMUROV0h2bndHMFZHTFV1NkFsbnowNi1rTTJySHdSZw?oc=5", "source_name": "TipRanks", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity receives Nasdaq notice for non-compliance with $35 million market value rule By Investing.com", "summary": "Celularity Inc. announced it received a Nasdaq notice for failing to maintain a minimum market value of $35 million for 30 consecutive business days. The company has 180 calendar days, until December 7, 2026, to regain compliance by having its market value of listed securities re", "url": "https://za.investing.com/news/sec-filings/celularity-receives-nasdaq-notice-for-noncompliance-with-35-million-market-value-rule-93CH-4326925", "source_name": "Investing.com South Africa", "published_at": "2026-06-13T15:41:04", "published_display": "13 Jun 2026 15:41", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Faces Nasdaq Listing Compliance Risk After Notice", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPeFJlaEFsc2piamxCOGN0QnRTd0dZcnNoRkV0VmhNd0lPeVFrSzYxTkN6eGhKSHBDR1lYLXhzN0EwelpHbkJiT25faGNTWVdSVW1rSWdiLTFyYWpBdVhrbXhvTFJjaVh0MzczMzJzaERDSzBYZ0J2cWlBSWhISVVUbDVQY0h1bmxGeTVHekRZYmlZYzktczlIdEhlckNubXV4LWRmR3p6TWNFTHlsWUhlNVdibU5NMVV5bVhmWkNweUtsSTBpdGs5bF9uQS1Nd2NnOTlpeW8tbFhGQld6M0E?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity receives Nasdaq notice for non-compliance with $35 million market value rule", "summary": "Celularity Inc. received a notice from Nasdaq for failing to meet the minimum market value of listed securities requirement of $35 million. The company has 180 calendar days, until December 7, 2026, to regain compliance, either by increasing its market value or by meeting alterna", "url": "https://ca.investing.com/news/sec-filings/celularity-receives-nasdaq-notice-for-noncompliance-with-35-million-market-value-rule-93CH-4689424", "source_name": "Investing.com Canada", "published_at": "2026-06-13T02:40:21", "published_display": "13 Jun 2026 02:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Celularity Inc Reports Material Event", "summary": "Celularity Inc. (CELU) has received a notice from Nasdaq stating that its Market Value of Listed Securities has fallen below the required $35 million minimum for 30 consecutive business days. The company has 180 calendar days, until December 7, 2026, to regain compliance by maint", "url": "https://www.stocktitan.net/sec-filings/CELU/8-k-celularity-inc-reports-material-event-93ffb430714f.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:20", "published_display": "12 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Received Notice of Noncompliance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPc21PN24zc19RcHNTU2VRYXRrWlZIYWhxYmlzQV9TZ1Vldm1NcWsxdjk4M1FuX0NQaVN0SmVzX200MWdkNFFjTFZDXzJHSDJUY25WajAzbW1sMVNuYjNtT2Zyal9kSHJWLWZxNVBnQXpOSzFrMXAwZTVYMExqMXZKUTlEWDQyLXh0UzloX2hVZE9fZHJJT0pMM1pLTXF1YjM1X0tZLTVwX1c?oc=5", "source_name": "TradingView", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celularity-fountain-life-announce-availability-120000012.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:00:00+00:00", "published_display": "04 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Releases CEO Letter to Shareholders", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celularity-releases-ceo-letter-shareholders-201500734.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T20:15:00+00:00", "published_display": "03 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Appoints Rick Gonzalez as Chief Commercial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celularity-appoints-rick-gonzalez-chief-120000808.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:00:00+00:00", "published_display": "03 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer, Effective May 29, 2026", "summary": "Celularity Inc. has appointed Rick Gonzalez as its Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will lead the global commercial strategy for cenplacel-L, Lifebank, and the company's broader regenerative medicine portfolio. He brings over two decade", "url": "https://www.marketscreener.com/news/celularity-inc-appoints-rick-gonzalez-as-chief-commercial-officer-effective-may-29-2026-ce7f5dddd18cf325", "source_name": "marketscreener.com", "published_at": "2026-06-01T05:41:07", "published_display": "01 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELU Stock Price and Chart \u2014 NASDAQ:CELU", "summary": "Celularity Inc. (NASDAQ: CELU) is a clinical-stage biotechnology company focused on developing allogeneic cell therapies from placental-derived sources for cancer, immune, and infectious diseases, operating through Cell Therapy, BioBanking, and Degenerative Disease segments. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-CELU/", "source_name": "TradingView", "published_at": "2026-05-31T08:10:05", "published_display": "31 May 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Receives Nasdaq Notice Regarding Form 10-Q", "summary": "Celularity Inc. announced it received a Nasdaq notification for non-compliance with Listing Rule 5250(c)(1) due to a delayed filing of its quarterly report on Form 10-Q. The company has 60 days to submit a compliance plan and is actively working to file the report as soon as prac", "url": "https://finance.yahoo.com/markets/stocks/articles/celularity-receives-nasdaq-notice-regarding-211500202.html", "source_name": "Market source", "published_at": "2026-05-29T17:15:00", "published_display": "29 May 2026 17:15", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) restructures Helena preferred stock deal with cash and note rights", "summary": "Celularity Inc. has settled a dispute with Helena Global Investment Opportunities 1 Ltd. regarding prior financing documents. The agreement involves Helena surrendering its Series A Convertible Preferred Stock in exchange for cash payments totaling $1 million ($500,000 immediatel", "url": "https://www.stocktitan.net/sec-filings/CELU/8-k-celularity-inc-reports-material-event-5f8b3060fbd1.html", "source_name": "Stock Titan", "published_at": "2026-05-29T08:39:35", "published_display": "29 May 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc. Notified of Non-Compliance with Nasdaq Listing Rule Due to Delayed 10-Q Filing | CELU Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNWi1OTkNLNVlKOVNvMFlvTE1QdlVjZmtYdW5Gd182QWJtX2FadTA1NTNDeE5wVVhVbmhfWEFwRUdpRzQzYW5qbm9DOGpVU001ZGpyY180ZXpfMGVhNXZNd2pCOS1UdGVpcGNLVTF4aVg5YURqLUlJYWdlcENKUEoxWWxsY2YtemFXZkhJaEVUa2FySXY5aV9QdHlGOXNLVFZvR1pneXJyUmpCZHRwZ1pFSFJuXzI2SUpNeVZWb3hZZExTZWFKRGc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Settles With Helena; $500,000 Upfront, 5x$100,000 Payments and $2.5M Note Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPNk92aUc5cU5PS2VaYldlT2dZcDZmVFpOUHkzcktGVy16cW1fcnVtLVltY1ZuTno0SGxsLTd0WUtOZVVTN3NTNDlqeWhndW1fN2hNeEhvMnhyd0dEbzZlZjNPSy12UUxXMEdxZzVKQTBjNG94LWZodmk5UHlJeG1kZGtjeTlYYmRuMzlPTjhtekp4dnNtVUNqcGdqcVVGb3EweXhnU293cDRyTTJtM0lIbWxVaW5ieUJVbVJvelQtYkkxRmFRZl9SRUsxMHpERUNwNXpkeXphMlNqZGNSZlFmTUVUcw?oc=5", "source_name": "TradingView", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Celularity (Nasdaq:CELU) - Stock Analysis", "summary": "This Simply Wall St analysis provides a detailed stock report for Celularity (Nasdaq:CELU), a regenerative and cellular medicines company, as of May 2026. The report covers valuation, future growth, past performance, financial health, dividend, management, and ownership, indicati", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celu/celularity", "source_name": "Simply Wall Street", "published_at": "2026-05-14T13:10:14", "published_display": "14 May 2026 13:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Celularity Regains Nasdaq Listing Compliance, Shares Rise", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/celularity-regains-nasdaq-listing-compliance-205305848.html", "source_name": "MT Newswires", "published_at": "2026-05-01T20:53:05+00:00", "published_display": "01 May 2026 20:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/celularity-announces-filing-form-10-203000677.html", "source_name": "GlobeNewswire", "published_at": "2026-05-01T20:30:00+00:00", "published_display": "01 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Barach Family Trust (CELU) reports warrants and convertible notes in Celularity Form 3", "summary": "The Philip & Daniele Barach Family Trust, a more than ten percent owner of Celularity Inc., has submitted a Form 3 filing detailing its existing holdings of warrants and convertible notes tied to Celularity\u2019s Class A common stock. The filing clarifies that these are existing deri", "url": "https://www.stocktitan.net/sec-filings/CELUW/form-3-celularity-inc-initial-statement-of-beneficial-ownership-33f2e1825c5d.html", "source_name": "Stock Titan", "published_at": "2026-04-24T23:10:49", "published_display": "24 Apr 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc (CELU) insider Form 3 details warrants and convertible notes", "summary": "A recently filed Form 3 reveals that Philip Alan Barach, through The Philip and Daniele Barach Family Trust, is a more than ten percent beneficial owner of Celularity Inc (CELU). The trust holds significant warrants and convertible notes, which can be converted into millions of s", "url": "https://www.stocktitan.net/sec-filings/CELU/form-3-celularity-inc-initial-statement-of-beneficial-ownership-ce2bb0132ee0.html", "source_name": "Stock Titan", "published_at": "2026-04-24T22:38:53", "published_display": "24 Apr 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Family trust reports 20.1% Celularity (CELU) stake from $10M financing", "summary": "The Philip & Daniele Barach Family Trust has disclosed an amended ownership report on Celularity Inc. (CELU), revealing a beneficial ownership of 7,558,665 Class A common shares, which represents a 20.1% stake. This stake originates from a $10 million financing deal on December 1", "url": "https://www.stocktitan.net/sec-filings/CELU/schedule-13d-a-celularity-inc-amended-major-shareholder-report-23095e6c7d8c.html", "source_name": "Stock Titan", "published_at": "2026-04-22T14:10:32", "published_display": "22 Apr 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexgel Inc co and Celularity enter amendment no. 1 to license agreement on April 17, 2026", "summary": "Nexgel Inc. and Celularity have executed Amendment No. 1 to their license agreement on April 17, 2026. This announcement by Reuters was published on April 21, 2026, at 06:27 pm EDT. The article also provides a company profile for Nexgel, Inc., detailing its focus on hydrogel prod", "url": "https://www.marketscreener.com/news/nexgel-inc-co-and-celularity-enter-amendment-no-1-to-license-agreement-on-april-17-2026-ce7f59dbd18af02c", "source_name": "www.marketscreener.com", "published_at": "2026-04-22T04:15:17", "published_display": "22 Apr 2026 04:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET", "summary": "NEXGEL, Inc. has announced the rescheduling of its shareholder update conference call to April 21, 2026, at 4:30 P.M. ET, moving it up from April 23rd. The call will focus on the Celularity transaction and provide updates from the company, a leading provider of hydrogel-based hea", "url": "https://finance.yahoo.com/markets/stocks/articles/nexgel-moves-forward-shareholder-call-193700495.html", "source_name": "Market source", "published_at": "2026-04-21T16:30:00", "published_display": "21 Apr 2026 16:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEXGEL New Strategic Partner, Sequence LifeScience\u2122, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nexgel-strategic-partner-sequence-lifescience-130000650.html", "source_name": "GlobeNewswire", "published_at": "2026-04-21T13:00:00+00:00", "published_display": "21 Apr 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) closes NexGel asset sale as Helena note default looms", "summary": "Celularity (NASDAQ: CELU) announced the closing of its NexGel asset sale, which generated $13.3 million in consideration and allowed the company to retire significant debt, enabling it to refocus on its core cell therapy platform. Concurrently, Celularity faces a looming default ", "url": "https://www.stocktitan.net/sec-filings/CELU/8-k-celularity-inc-reports-material-event-3ce3791eea76.html", "source_name": "Stock Titan", "published_at": "2026-04-21T13:08:57", "published_display": "21 Apr 2026 13:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing", "summary": "Celularity Inc. announced it received a notice from Nasdaq regarding its non-compliance with Listing Rule 5250(c)(1) for failing to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company has 60 calendar days to submit a plan to regain ", "url": "https://finance.yahoo.com/markets/stocks/articles/celularity-announces-receipt-nasdaq-notice-203500353.html", "source_name": "Market source", "published_at": "2026-04-17T10:40:14", "published_display": "17 Apr 2026 10:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) CEO gains shares from RSU vesting", "summary": "Celularity Inc. CEO Robert J. Hariri acquired 3,281 shares of Class A Common Stock from the vesting of Restricted Stock Units (RSUs) on April 13, 2026. This transaction represents 25% of an original 13,123-RSU award granted in 2022. To cover tax obligations, 1,182 shares were wit", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-d45f53f9c554.html", "source_name": "Stock Titan", "published_at": "2026-04-15T20:40:53", "published_display": "15 Apr 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU vesting lifts Celularity (CELU) insider holdings after tax withholding", "summary": "Celularity Inc. executive Stephen Brigido reported the vesting of 821 restricted stock units (RSUs) on April 13, 2026, which converted into Class A Common Stock. To cover tax obligations, 268 shares were withheld at $1.28 per share, resulting in a net increase of 553 shares to hi", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-8f89f672cb6b.html", "source_name": "Stock Titan", "published_at": "2026-04-15T20:40:53", "published_display": "15 Apr 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) EVP RSUs vest into shares with tax withholding", "summary": "Celularity Inc.'s Senior Executive Vice President, John R. Haines, had 1,641 restricted stock units (RSUs) vest and convert into Class A common stock. These RSUs were part of a larger grant from April 2022, with 25% vesting on April 13, 2026. To cover tax obligations, 583 shares ", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-b3fabb0300a0.html", "source_name": "Stock Titan", "published_at": "2026-04-15T20:39:48", "published_display": "15 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction", "summary": "NEXGEL, Inc. has rescheduled its shareholder update conference call to April 15, 2026, at 4:30 P.M. ET to provide an update on the Celularity transaction. The company will not be financing the transaction under its previously announced Securities Purchase Agreement but is negotia", "url": "https://www.manilatimes.net/2026/04/09/tmt-newswire/globenewswire/nexgel-reschedules-shareholder-update-conference-call-to-april-15th-at-430-pm-et-to-provide-update-on-celularity-transaction/2316795/amp", "source_name": "The Manila Times", "published_at": "2026-04-08T20:40:32", "published_display": "08 Apr 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barach Family Trust Secures Board Observer Role at Celularity with 9.56% Stake", "summary": "The Philip & Daniele Barach Family Trust has disclosed a 9.56% stake in Celularity Inc.'s Class A common stock, encompassing convertible notes that could yield over 3 million shares. This investment grants the Trust a board observer role and the flexibility to influence strategic", "url": "https://www.tradingview.com/news/tradingview:33158cef75345:0-barach-family-trust-secures-board-observer-role-at-celularity-with-9-56-stake/", "source_name": "TradingView", "published_at": "2026-04-03T15:40:08", "published_display": "03 Apr 2026 15:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELU SEC Filings - Celularity Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE0zS1Bud3ByeHc0ZFhoa3JJdnhpRGk5VWlOT0lMbFphSVFQdHVxcW8zWDdHWFdtVVVGbVhudDdhMnZBa0xKb1BMTnJlaExVV2JsUHVBS3JLdw?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-10T04:38:21+00:00", "published_display": "10 Jul 2025 04:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (CELU) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1ubzRTdXdpb1VWZ04yTHBJTUF6ekpfY3BabTU5VVNvYmF3TmlJNk9YcngyS1hzQ2RkOXA4Y1NkQXJvdEQ1SlhrcDV2SjBCSjdCak9n?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:46:46+00:00", "published_display": "25 Apr 2025 00:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Partners with Genting Berhad to Launch Stem Cell Therapies in Asia Pacific with New Facility in Bali", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOVldEd1FVUGRZdEUzaTdoVEhURHNSNUFIdXdOODFXejJKRUNLY0Q3c2s4aFQxUzE4VHRXUzAtbjkwbTE2Z0dDMzRteTBQREM3a3dMdkxZSXZVRGxlYlJBazRqRGRMdGFuVHRiS2tnd0h4Q1hnYVVLckpic2E5VXZYM3U2UEZrOFlUNVZRX3dFc1Z6cXRIMVdxaTd3WlB1bXFGZ1QwOEpmZ2J5d0dSWTF5UDhOY3NZTHZpUkJHVnNSWlYycm4tczRscGFTRGlHckh5cnEya2pWMnp4SVZY?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-11-20T08:00:00+00:00", "published_display": "20 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity warns of layoffs for \u2018substantial portion\u2019 of its staff", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNSkxnWXlmUmtiN2pLdER0SEZDQjlvRExZU3VVTnRzQllvUDVnYUo5VmhFR01YamU2cndRdjJ6eXNxeDJoQkFJaHNmd2VROFljM1FwUnQ4QmxydEdkSU1qcFdldkR4d0JfX2dqa2cybVBaa3RTbjRvUE1NYzROTjRNejAtcnBHRlJ0VXlGOUFCSUtETFEzdHh0Y2FKVDM?oc=5", "source_name": "BioPharma Dive", "published_at": "2023-01-27T08:00:00+00:00", "published_display": "27 Jan 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity, clinical-stage cellular medicine company, goes public following $138 million merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPZnp2Rm5GcWtTTWhJb0FMMVh0LWp5VFhFYUFiekVnbkRBckp1SjBmUE9rM0pibTB1YUJYX0RoMGMxY3dNUnhoMGRGZkoyRi1WZi1uNUtvZ2JoNlpaRVJpUUhXaVgxOWVLQ1NwZW8tQTNnX1NqV21LbkNfXzJ4TUZVQXRleUlaVFNrR0lIRHlEc2NIdDF0Z3VHdWNxRThPcmFHVVh4Tk9IX0tFT1lqMGg5X1pjaEhkVmVOcExmNnpmNHE4d3FuT1BaUHhB?oc=5", "source_name": "Medical Economics", "published_at": "2021-07-16T07:00:00+00:00", "published_display": "16 Jul 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Insider trust lends $1M to Celularity (NASDAQ: CELU) on short term", "summary": "Celularity Inc. has secured a $1 million short-term loan from the Philip & Daniele Barach Family Trust, an entity linked to a significant shareholder. The loan features a 4.0% annual interest rate, which can rise to 18.0% upon default, and is collateralized by most of Celularity'", "url": "https://www.stocktitan.net/sec-filings/CELU/8-k-celularity-inc-reports-material-event-3578c6e71049.html", "source_name": "Stock Titan", "published_at": "2026-06-30T22:09:35", "published_display": "30 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc. Enters into a Loan Agreement with the Philip & Daniele Barach Family Trust", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQd2xIZ0NmaXU1eExmWlRoMEwyNHA0S0FSYXhhMEJXSDRIMlBOa2pIc0tkV1RxcU5qQTdGc1NBbHZYd2t4aGxXbXBMelVJdnRMcXZwVnVaS1Q1UDVwRGNObnhYWlVEemRQdzFKb2l2YnpMT1Y5VF83TzcyLWJWektJTVBvdUxpNGhXSk4wT041X2NWUzFRd3RJdkJ6aEc4Yk9FcjRyVTRyZ3luTzZndng1dTZCcWhmTnR5T1QxQnE3RjEyWGFGZkdzS0pBSjRzQ0JuaXNYS3RWcw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-30T19:35:42+00:00", "published_display": "30 Jun 2026 19:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc (NASDAQ: CELU) Share Price, CELU Stock News, CELU Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE1IX1NTTlpDMERiVko1ajlCMkhLUVFmV1Iyc2FreU1LRXRKWEtwUTdaN1MweEd0T2xDbmZaRTR4aGdaQzN1VHZtTGNhSnhLbHdGRG9IczNn?oc=5", "source_name": "Kalkine", "published_at": "2026-06-29T10:46:46+00:00", "published_display": "29 Jun 2026 10:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Appoints Chief Operating Officer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/celularity-appoints-chief-operating-officer-094945297.html", "source_name": "MT Newswires", "published_at": "2026-06-26T09:49:45+00:00", "published_display": "26 Jun 2026 09:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc. Class A Actuals & Estimates (NASDAQ:CELU)", "summary": "This article provides an overview of Celularity Inc. (NASDAQ: CELU) stock, including its current price, market capitalization, volatility, and historical performance. It also details financial information such as net income, EBITDA, and the upcoming earnings release date, along w", "url": "https://www.tradingview.com/symbols/NASDAQ-CELU/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:12:30", "published_display": "25 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 10, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New leadership at Celularity (NASDAQ: CELU) as Gordon joins board", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxORG5lN3hXT3FwcVRKVTVSN2sxc2tQY1hPd3hpZXdVVmdvME1PbENLRzdwMENjb28zc1RpcGU0dHZYS24wXzNoMk02R3F5WmlhMnpJRFVRTzBGTVNtWm1SYmJlLXhGcWZidE02Y0Frc1FEd3loOUttSFZ6WkhvWF9xRjRnNWpzRjBBSFFVRDhsMWRmMVN3bGdPOGhMblpzUUk5RVJ2dEhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc. (CELU) Q4 2025 Earnings: Narrowed Loss Beats Estimates, but Revenue Remains Absent - Diluted EPS Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOWFdieVp3dmNuNjFJSUJabHA2VmVMeVpzVGJPVGdLTTZBN3Q2WXJGZFo2V2tkY1ZtamNPSGQ3YUJkQkY4UkdJWGZVdnp0VXZZUnRYMkRqU0FTWU5tQUxDTWhEeFRRZEhrVVJ5bVpwUm9raGtXcGpVc0JPLTdTWEJicmljTkM1TmVmTmoyd0NXNjVrMWR3LURiVTl2T3ltcDJoLVJQc0FTYWZPUExYOWZaeHVLbGRfQjZpMnhuZGFvck9IMHRXbUtRNGRjS2VoenFnaHhkeVVKbGU?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Celularity Inc For: 23 June By Investing.com", "summary": "This article confirms that a Form 4 filing for Celularity Inc. was made on June 23rd, as reported by Investing.com. It also briefly mentions Celularity Inc.'s stock symbol CELU and its performance. The rest of the content includes current market data for various indices, commodit", "url": "https://ng.investing.com/news/stock-market-news/form-4-celularity-inc-for-23-june-93CH-2570399", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T19:10:35", "published_display": "23 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) insider trust sees $2M note option expire", "summary": "A Form 4 filing reveals that options held by The Philip & Daniele Barach Family Trust, a ten percent owner of Celularity (NASDAQ: CELU), to purchase up to $2,000,000 in convertible notes and 839,160 related warrants, expired on June 19, 2026. The expiration occurred as per the te", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-0d6ae59ebe9e.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:11:47", "published_display": "23 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barach Family Trust (CELU) lets $2M note, warrant options lapse while holding large derivatives", "summary": "The Philip & Daniele Barach Family Trust, a 10% owner of Celularity Inc. (CELU), reported that options to purchase $2 million in convertible notes and 839,160 warrants expired on June 19, 2026, without consideration. Despite these expirations, the trust maintains significant hold", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-bac6c5ce9bad.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:11:47", "published_display": "23 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) major holder\u2019s $2M note option and 839K warrants expire", "summary": "A major shareholder of Celularity Inc., Daniele Wolf Barach, through the Philip & Daniele Barach Family Trust, reported the expiration of options to purchase up to $2 million in convertible notes and rights to obtain 839,160 warrants. These options expired on June 19, 2026, witho", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-cb12e457913a.html", "source_name": "Stock Titan", "published_at": "2026-06-23T14:11:47", "published_display": "23 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Celularity Inc. For: 23 June By Investing.com", "summary": "This article announces the filing of Form 13D/A by Celularity Inc. on June 23, 2026. Form 13D/A is a regulatory filing indicating a change in beneficial ownership of a company's shares. The article provides no further details about the filing's content.", "url": "https://ng.investing.com/news/stock-market-news/form-13da-celularity-inc-for-23-june-93CH-2569437", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T07:09:59", "published_display": "23 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penny Stocks: Why Is Celularity (CELU) Stock Trending Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPSld5eEhZLVpzWEJGTWhFak9DZExLZ2dFbmNpMHFtbVJxTGt0WHRqdGJWZWJGcVJ4dmFkMVRmQjJrQkczVUoxQnM5Zm9IZlBzQzNsNXdoekZrenZPRXYtZTVLRUQ1YnIyNWZ1MF9QMzFXMUROV0h2bndHMFZHTFV1NkFsbnowNi1rTTJySHdSZw?oc=5", "source_name": "TipRanks", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity receives Nasdaq notice for non-compliance with $35 million market value rule By Investing.com", "summary": "Celularity Inc. announced it received a Nasdaq notice for failing to maintain a minimum market value of $35 million for 30 consecutive business days. The company has 180 calendar days, until December 7, 2026, to regain compliance by having its market value of listed securities re", "url": "https://za.investing.com/news/sec-filings/celularity-receives-nasdaq-notice-for-noncompliance-with-35-million-market-value-rule-93CH-4326925", "source_name": "Investing.com South Africa", "published_at": "2026-06-13T15:41:04", "published_display": "13 Jun 2026 15:41", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Faces Nasdaq Listing Compliance Risk After Notice", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPeFJlaEFsc2piamxCOGN0QnRTd0dZcnNoRkV0VmhNd0lPeVFrSzYxTkN6eGhKSHBDR1lYLXhzN0EwelpHbkJiT25faGNTWVdSVW1rSWdiLTFyYWpBdVhrbXhvTFJjaVh0MzczMzJzaERDSzBYZ0J2cWlBSWhISVVUbDVQY0h1bmxGeTVHekRZYmlZYzktczlIdEhlckNubXV4LWRmR3p6TWNFTHlsWUhlNVdibU5NMVV5bVhmWkNweUtsSTBpdGs5bF9uQS1Nd2NnOTlpeW8tbFhGQld6M0E?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity receives Nasdaq notice for non-compliance with $35 million market value rule", "summary": "Celularity Inc. received a notice from Nasdaq for failing to meet the minimum market value of listed securities requirement of $35 million. The company has 180 calendar days, until December 7, 2026, to regain compliance, either by increasing its market value or by meeting alterna", "url": "https://ca.investing.com/news/sec-filings/celularity-receives-nasdaq-notice-for-noncompliance-with-35-million-market-value-rule-93CH-4689424", "source_name": "Investing.com Canada", "published_at": "2026-06-13T02:40:21", "published_display": "13 Jun 2026 02:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Celularity Inc Reports Material Event", "summary": "Celularity Inc. (CELU) has received a notice from Nasdaq stating that its Market Value of Listed Securities has fallen below the required $35 million minimum for 30 consecutive business days. The company has 180 calendar days, until December 7, 2026, to regain compliance by maint", "url": "https://www.stocktitan.net/sec-filings/CELU/8-k-celularity-inc-reports-material-event-93ffb430714f.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:20", "published_display": "12 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Received Notice of Noncompliance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPc21PN24zc19RcHNTU2VRYXRrWlZIYWhxYmlzQV9TZ1Vldm1NcWsxdjk4M1FuX0NQaVN0SmVzX200MWdkNFFjTFZDXzJHSDJUY25WajAzbW1sMVNuYjNtT2Zyal9kSHJWLWZxNVBnQXpOSzFrMXAwZTVYMExqMXZKUTlEWDQyLXh0UzloX2hVZE9fZHJJT0pMM1pLTXF1YjM1X0tZLTVwX1c?oc=5", "source_name": "TradingView", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celularity-fountain-life-announce-availability-120000012.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:00:00+00:00", "published_display": "04 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Releases CEO Letter to Shareholders", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celularity-releases-ceo-letter-shareholders-201500734.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T20:15:00+00:00", "published_display": "03 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Appoints Rick Gonzalez as Chief Commercial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celularity-appoints-rick-gonzalez-chief-120000808.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:00:00+00:00", "published_display": "03 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer, Effective May 29, 2026", "summary": "Celularity Inc. has appointed Rick Gonzalez as its Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will lead the global commercial strategy for cenplacel-L, Lifebank, and the company's broader regenerative medicine portfolio. He brings over two decade", "url": "https://www.marketscreener.com/news/celularity-inc-appoints-rick-gonzalez-as-chief-commercial-officer-effective-may-29-2026-ce7f5dddd18cf325", "source_name": "marketscreener.com", "published_at": "2026-06-01T05:41:07", "published_display": "01 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELU Stock Price and Chart \u2014 NASDAQ:CELU", "summary": "Celularity Inc. (NASDAQ: CELU) is a clinical-stage biotechnology company focused on developing allogeneic cell therapies from placental-derived sources for cancer, immune, and infectious diseases, operating through Cell Therapy, BioBanking, and Degenerative Disease segments. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-CELU/", "source_name": "TradingView", "published_at": "2026-05-31T08:10:05", "published_display": "31 May 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Receives Nasdaq Notice Regarding Form 10-Q", "summary": "Celularity Inc. announced it received a Nasdaq notification for non-compliance with Listing Rule 5250(c)(1) due to a delayed filing of its quarterly report on Form 10-Q. The company has 60 days to submit a compliance plan and is actively working to file the report as soon as prac", "url": "https://finance.yahoo.com/markets/stocks/articles/celularity-receives-nasdaq-notice-regarding-211500202.html", "source_name": "Market source", "published_at": "2026-05-29T17:15:00", "published_display": "29 May 2026 17:15", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) restructures Helena preferred stock deal with cash and note rights", "summary": "Celularity Inc. has settled a dispute with Helena Global Investment Opportunities 1 Ltd. regarding prior financing documents. The agreement involves Helena surrendering its Series A Convertible Preferred Stock in exchange for cash payments totaling $1 million ($500,000 immediatel", "url": "https://www.stocktitan.net/sec-filings/CELU/8-k-celularity-inc-reports-material-event-5f8b3060fbd1.html", "source_name": "Stock Titan", "published_at": "2026-05-29T08:39:35", "published_display": "29 May 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc. Notified of Non-Compliance with Nasdaq Listing Rule Due to Delayed 10-Q Filing | CELU Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNWi1OTkNLNVlKOVNvMFlvTE1QdlVjZmtYdW5Gd182QWJtX2FadTA1NTNDeE5wVVhVbmhfWEFwRUdpRzQzYW5qbm9DOGpVU001ZGpyY180ZXpfMGVhNXZNd2pCOS1UdGVpcGNLVTF4aVg5YURqLUlJYWdlcENKUEoxWWxsY2YtemFXZkhJaEVUa2FySXY5aV9QdHlGOXNLVFZvR1pneXJyUmpCZHRwZ1pFSFJuXzI2SUpNeVZWb3hZZExTZWFKRGc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Settles With Helena; $500,000 Upfront, 5x$100,000 Payments and $2.5M Note Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPNk92aUc5cU5PS2VaYldlT2dZcDZmVFpOUHkzcktGVy16cW1fcnVtLVltY1ZuTno0SGxsLTd0WUtOZVVTN3NTNDlqeWhndW1fN2hNeEhvMnhyd0dEbzZlZjNPSy12UUxXMEdxZzVKQTBjNG94LWZodmk5UHlJeG1kZGtjeTlYYmRuMzlPTjhtekp4dnNtVUNqcGdqcVVGb3EweXhnU293cDRyTTJtM0lIbWxVaW5ieUJVbVJvelQtYkkxRmFRZl9SRUsxMHpERUNwNXpkeXphMlNqZGNSZlFmTUVUcw?oc=5", "source_name": "TradingView", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (Nasdaq:CELU) - Stock Analysis", "summary": "This Simply Wall St analysis provides a detailed stock report for Celularity (Nasdaq:CELU), a regenerative and cellular medicines company, as of May 2026. The report covers valuation, future growth, past performance, financial health, dividend, management, and ownership, indicati", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celu/celularity", "source_name": "Simply Wall Street", "published_at": "2026-05-14T13:10:14", "published_display": "14 May 2026 13:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Regains Nasdaq Listing Compliance, Shares Rise", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/celularity-regains-nasdaq-listing-compliance-205305848.html", "source_name": "MT Newswires", "published_at": "2026-05-01T20:53:05+00:00", "published_display": "01 May 2026 20:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/celularity-announces-filing-form-10-203000677.html", "source_name": "GlobeNewswire", "published_at": "2026-05-01T20:30:00+00:00", "published_display": "01 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barach Family Trust (CELU) reports warrants and convertible notes in Celularity Form 3", "summary": "The Philip & Daniele Barach Family Trust, a more than ten percent owner of Celularity Inc., has submitted a Form 3 filing detailing its existing holdings of warrants and convertible notes tied to Celularity\u2019s Class A common stock. The filing clarifies that these are existing deri", "url": "https://www.stocktitan.net/sec-filings/CELUW/form-3-celularity-inc-initial-statement-of-beneficial-ownership-33f2e1825c5d.html", "source_name": "Stock Titan", "published_at": "2026-04-24T23:10:49", "published_display": "24 Apr 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Inc (CELU) insider Form 3 details warrants and convertible notes", "summary": "A recently filed Form 3 reveals that Philip Alan Barach, through The Philip and Daniele Barach Family Trust, is a more than ten percent beneficial owner of Celularity Inc (CELU). The trust holds significant warrants and convertible notes, which can be converted into millions of s", "url": "https://www.stocktitan.net/sec-filings/CELU/form-3-celularity-inc-initial-statement-of-beneficial-ownership-ce2bb0132ee0.html", "source_name": "Stock Titan", "published_at": "2026-04-24T22:38:53", "published_display": "24 Apr 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Family trust reports 20.1% Celularity (CELU) stake from $10M financing", "summary": "The Philip & Daniele Barach Family Trust has disclosed an amended ownership report on Celularity Inc. (CELU), revealing a beneficial ownership of 7,558,665 Class A common shares, which represents a 20.1% stake. This stake originates from a $10 million financing deal on December 1", "url": "https://www.stocktitan.net/sec-filings/CELU/schedule-13d-a-celularity-inc-amended-major-shareholder-report-23095e6c7d8c.html", "source_name": "Stock Titan", "published_at": "2026-04-22T14:10:32", "published_display": "22 Apr 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexgel Inc co and Celularity enter amendment no. 1 to license agreement on April 17, 2026", "summary": "Nexgel Inc. and Celularity have executed Amendment No. 1 to their license agreement on April 17, 2026. This announcement by Reuters was published on April 21, 2026, at 06:27 pm EDT. The article also provides a company profile for Nexgel, Inc., detailing its focus on hydrogel prod", "url": "https://www.marketscreener.com/news/nexgel-inc-co-and-celularity-enter-amendment-no-1-to-license-agreement-on-april-17-2026-ce7f59dbd18af02c", "source_name": "www.marketscreener.com", "published_at": "2026-04-22T04:15:17", "published_display": "22 Apr 2026 04:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET", "summary": "NEXGEL, Inc. has announced the rescheduling of its shareholder update conference call to April 21, 2026, at 4:30 P.M. ET, moving it up from April 23rd. The call will focus on the Celularity transaction and provide updates from the company, a leading provider of hydrogel-based hea", "url": "https://finance.yahoo.com/markets/stocks/articles/nexgel-moves-forward-shareholder-call-193700495.html", "source_name": "Market source", "published_at": "2026-04-21T16:30:00", "published_display": "21 Apr 2026 16:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEXGEL New Strategic Partner, Sequence LifeScience\u2122, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nexgel-strategic-partner-sequence-lifescience-130000650.html", "source_name": "GlobeNewswire", "published_at": "2026-04-21T13:00:00+00:00", "published_display": "21 Apr 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) closes NexGel asset sale as Helena note default looms", "summary": "Celularity (NASDAQ: CELU) announced the closing of its NexGel asset sale, which generated $13.3 million in consideration and allowed the company to retire significant debt, enabling it to refocus on its core cell therapy platform. Concurrently, Celularity faces a looming default ", "url": "https://www.stocktitan.net/sec-filings/CELU/8-k-celularity-inc-reports-material-event-3ce3791eea76.html", "source_name": "Stock Titan", "published_at": "2026-04-21T13:08:57", "published_display": "21 Apr 2026 13:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing", "summary": "Celularity Inc. announced it received a notice from Nasdaq regarding its non-compliance with Listing Rule 5250(c)(1) for failing to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company has 60 calendar days to submit a plan to regain ", "url": "https://finance.yahoo.com/markets/stocks/articles/celularity-announces-receipt-nasdaq-notice-203500353.html", "source_name": "Market source", "published_at": "2026-04-17T10:40:14", "published_display": "17 Apr 2026 10:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) CEO gains shares from RSU vesting", "summary": "Celularity Inc. CEO Robert J. Hariri acquired 3,281 shares of Class A Common Stock from the vesting of Restricted Stock Units (RSUs) on April 13, 2026. This transaction represents 25% of an original 13,123-RSU award granted in 2022. To cover tax obligations, 1,182 shares were wit", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-d45f53f9c554.html", "source_name": "Stock Titan", "published_at": "2026-04-15T20:40:53", "published_display": "15 Apr 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU vesting lifts Celularity (CELU) insider holdings after tax withholding", "summary": "Celularity Inc. executive Stephen Brigido reported the vesting of 821 restricted stock units (RSUs) on April 13, 2026, which converted into Class A Common Stock. To cover tax obligations, 268 shares were withheld at $1.28 per share, resulting in a net increase of 553 shares to hi", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-8f89f672cb6b.html", "source_name": "Stock Titan", "published_at": "2026-04-15T20:40:53", "published_display": "15 Apr 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (NASDAQ: CELU) EVP RSUs vest into shares with tax withholding", "summary": "Celularity Inc.'s Senior Executive Vice President, John R. Haines, had 1,641 restricted stock units (RSUs) vest and convert into Class A common stock. These RSUs were part of a larger grant from April 2022, with 25% vesting on April 13, 2026. To cover tax obligations, 583 shares ", "url": "https://www.stocktitan.net/sec-filings/CELU/form-4-celularity-inc-insider-trading-activity-b3fabb0300a0.html", "source_name": "Stock Titan", "published_at": "2026-04-15T20:39:48", "published_display": "15 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction", "summary": "NEXGEL, Inc. has rescheduled its shareholder update conference call to April 15, 2026, at 4:30 P.M. ET to provide an update on the Celularity transaction. The company will not be financing the transaction under its previously announced Securities Purchase Agreement but is negotia", "url": "https://www.manilatimes.net/2026/04/09/tmt-newswire/globenewswire/nexgel-reschedules-shareholder-update-conference-call-to-april-15th-at-430-pm-et-to-provide-update-on-celularity-transaction/2316795/amp", "source_name": "The Manila Times", "published_at": "2026-04-08T20:40:32", "published_display": "08 Apr 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barach Family Trust Secures Board Observer Role at Celularity with 9.56% Stake", "summary": "The Philip & Daniele Barach Family Trust has disclosed a 9.56% stake in Celularity Inc.'s Class A common stock, encompassing convertible notes that could yield over 3 million shares. This investment grants the Trust a board observer role and the flexibility to influence strategic", "url": "https://www.tradingview.com/news/tradingview:33158cef75345:0-barach-family-trust-secures-board-observer-role-at-celularity-with-9-56-stake/", "source_name": "TradingView", "published_at": "2026-04-03T15:40:08", "published_display": "03 Apr 2026 15:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPSFFtcXJXdGxKX3N0T3FSZkFscXFKVWM1OWtDVXIySG95YzNqSVYycGhlNWwtUmJ2SV9RZDhjQTc3NWpQX2QxclplU0E1OU1CUmNFczhOVnBiUFhucG1GNHVCeXFOdVJ6XzhCWHF4TG8xbzduYjBWXzQyUm9uR0ota0FGNEthNDZOU1Ztay1iWFdlTnpRWWhsMl9TRzFfMFI5M2thWGlXRjU1T204Tm52N0pUUFlTaW4zMk4xdXJ2aTlGazF4WDA5SmpyVlBGdDByVlVuYnpYUm9uaWt40gHiAUFVX3lxTE5UQnZFZTBIRzR5WFNOeXZLSFM2ZndOdkRvSi1kWFpBZ196NElSNFZfNWVySW1taS1KYmxjM0xOTFBZZFhaZUY0Q3hWMDk3UV9FU29ERUxBU0h4OXBoUGQwWnU4Sm1DcjNnVW9UdVQ5VWIxbmtUbUQyRHFBYjRNRGdzN01zOFJub0xWd2VKV1hjLUZxeTZQZ0o0TUFiN0dfRmEtMXl5VTdwb2NieDJhc3JrTXFkSl9sRTVSakdYejlXYkZ6TnlzSTRZRFJsc0ZRT2xGcWJiU1dROVZOcm9ZZGZUUXc?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELU SEC Filings - Celularity Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE0zS1Bud3ByeHc0ZFhoa3JJdnhpRGk5VWlOT0lMbFphSVFQdHVxcW8zWDdHWFdtVVVGbVhudDdhMnZBa0xKb1BMTnJlaExVV2JsUHVBS3JLdw?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-10T04:38:21+00:00", "published_display": "10 Jul 2025 04:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity (CELU) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1ubzRTdXdpb1VWZ04yTHBJTUF6ekpfY3BabTU5VVNvYmF3TmlJNk9YcngyS1hzQ2RkOXA4Y1NkQXJvdEQ1SlhrcDV2SjBCSjdCak9n?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:46:46+00:00", "published_display": "25 Apr 2025 00:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity Partners with Genting Berhad to Launch Stem Cell Therapies in Asia Pacific with New Facility in Bali", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOVldEd1FVUGRZdEUzaTdoVEhURHNSNUFIdXdOODFXejJKRUNLY0Q3c2s4aFQxUzE4VHRXUzAtbjkwbTE2Z0dDMzRteTBQREM3a3dMdkxZSXZVRGxlYlJBazRqRGRMdGFuVHRiS2tnd0h4Q1hnYVVLckpic2E5VXZYM3U2UEZrOFlUNVZRX3dFc1Z6cXRIMVdxaTd3WlB1bXFGZ1QwOEpmZ2J5d0dSWTF5UDhOY3NZTHZpUkJHVnNSWlYycm4tczRscGFTRGlHckh5cnEya2pWMnp4SVZY?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-11-20T08:00:00+00:00", "published_display": "20 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity warns of layoffs for \u2018substantial portion\u2019 of its staff", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNSkxnWXlmUmtiN2pLdER0SEZDQjlvRExZU3VVTnRzQllvUDVnYUo5VmhFR01YamU2cndRdjJ6eXNxeDJoQkFJaHNmd2VROFljM1FwUnQ4QmxydEdkSU1qcFdldkR4d0JfX2dqa2cybVBaa3RTbjRvUE1NYzROTjRNejAtcnBHRlJ0VXlGOUFCSUtETFEzdHh0Y2FKVDM?oc=5", "source_name": "BioPharma Dive", "published_at": "2023-01-27T08:00:00+00:00", "published_display": "27 Jan 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celularity, clinical-stage cellular medicine company, goes public following $138 million merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPZnp2Rm5GcWtTTWhJb0FMMVh0LWp5VFhFYUFiekVnbkRBckp1SjBmUE9rM0pibTB1YUJYX0RoMGMxY3dNUnhoMGRGZkoyRi1WZi1uNUtvZ2JoNlpaRVJpUUhXaVgxOWVLQ1NwZW8tQTNnX1NqV21LbkNfXzJ4TUZVQXRleUlaVFNrR0lIRHlEc2NIdDF0Z3VHdWNxRThPcmFHVVh4Tk9IX0tFT1lqMGg5X1pjaEhkVmVOcExmNnpmNHE4d3FuT1BaUHhB?oc=5", "source_name": "Medical Economics", "published_at": "2021-07-16T07:00:00+00:00", "published_display": "16 Jul 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 57, "sentiment_summary": {"positive": 3, "negative": 10, "neutral": 44, "score": 47, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 20.9, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 4.4, "count": 10}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 3, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 0.74, "latest_week": "2026-07-10", "one_week_move": 19.5, "four_week_move": 3.9, "twelve_week_move": -39.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.709092, "market_dynamics_buy_signal": false, "relative_strength": -62.994368, "fair_value_gap": -69.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.0535, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+19.5% over one week, +3.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 16}, {"label": "Market source", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "simplywall.st", "count": 3}, {"label": "marketscreener.com", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 10}, {"label": "Deals and strategy", "count": 5}, {"label": "Regulatory and legal", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "47/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+19.5% over one week, +3.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Insider trust lends $1M to Celularity (NASDAQ: CELU) on short term"}], "updated_at": "2026-07-16T04:34:37.625093+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}